The short version of peptide analog fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-28. Anything still debated is marked as such rather than presented as settled.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
== Industry applications == The liquid chromatography marketplace is incredibly diverse. Five to ten firms are consistently market leaders, yet nearly half of the market is made up of small, fragmented companies. This section of the report will focus on the roles that a few companies have had in bringing monolith column technologies to the commercial market. In 1998, start-up biotechnology company BIA Separations of Ljubljana, Slovenia, came into being. The technology was originally developed by Tatiana Tennikova and Frantisek Svec during a collaboration between their respective institutes. The patent for these columns was acquired by BIA Separations and Ales Podgornik and Milos Barut developed the first commercially available monolith column in the form of a short disc encapsulated in a plastic housing. Trademarked CIM, BIA Separations has since introduced full lines of reversed-phase, normal-phase, ion-exchange, and affinity polymeric monoliths. Ales Podgornik and Janez Jancar then went on to develop large scale tube monolithic columns for industrial use. The largest column currently available is 8L. In May 2008, LC instrumentation powerhouse Agilent technologies agreed to market BIA Separations’ analytical columns based on monolith technology. Agilent's commercialized the columns with strong and weak ion exchange phases and Protein A in September 2008 when they unveiled their new Bio-Monolith product line at the BioProcess International conference.
Produced by Charles Konowal, directed by Stephen Low, made by Uden Associates and National Film Board of Canada 27 August Little by Little, about Eric Drexler and nanotechnology. Produced by David Kennard, directed by Karl Sabbagh, made by InCA 3 September Woomera, a rocket base for over 30 years; set up by Sir John Events; rockets arrived in 1949, and the Australian Security Intelligence Organisation (ASIO) needed to be set up as sensitive information had leaked to the Soviets; the Weapons Research Establishment was set up at Edinburgh, South Australia, which is now largely RAAF Base Edinburgh; the GAF Jindivik target drone was developed in 1952; up to 6 or 7 guided missiles would be launched per day; the Malkara and Stanley Schatzel (1924-2015), technical director from 1970 to 1989 for Hawker Siddeley Dynamics; the drop of the Blue Danube by No.
The two Δ formulas are frequently used to report the abundance of clumped isotopologues of methane. The reason for choosing stochastic distribution as the reference frame may be historical - in the process of developing CO2 clumped isotope measurement, the only material with known clumped isotope abundance was CO2 heated to 1000 °C. However, this reference frame is a good choice. Because the absolute abundance of each isotopologue primarily depends on the bulk carbon and hydrogen isotope compositions (δ13C and δD) of the molecules, i.e. very close to stochastic distribution. Therefore, the deviation from the stochastic distribution, which is the key information embedded in the methane clumped isotopologues, is denoted by Δ values.
Sources: en.wikipedia.org
== Division of Scientific Education and Professional Development == The Division of Scientific Education and Professional Development (DSEPD) provides leadership for recruiting, training, developing and retaining the nation's public health workforce at all levels of the public health system.
== Genetics == Contrary to bacteria and fungi, most plant metabolic pathways are not grouped into biosynthetic gene clusters, but instead are scattered as individual genes. Some exceptions have been discovered: steroidal glycoalkaloids in Solanum, polyketides in Pooideae, benzoxazinoids in Zea mays, triterpenes in Avena sativa, Cucurbitaceae, Arabidopsis, and momilactone diterpenes in Oryza sativa.
=== Non-destructive sampling protocols === Although the ammonium bicarbonate protocol should not be considered a non-destructive method, it was followed by more 'true' non-destructive methods. The first of these was the eraser protocol, first tested on parchment, but later also applied to bone. The eraser protocol is performed by rubbing a PVC eraser on a piece of parchment or bone. The friction generates triboelectric forces, which causes small particles of the sample to cling to the eraser waste. From the eraser waste collagen can then be extracted and analysed. The eraser protocol was found to work relatively well for parchment, but it is less effective on bone. Additionally, it leaves microscopic traces on the bone surface, which appear very similar to use wear traces and could be an issue for use wear analysis. A second non-destructive protocol is the plastic bag protocol, first published in 2019. It is based on the idea that the normal friction between an object and the plastic bags, commonly used for storing archaeological objects, might be sufficient to extract enough material for ZooMS analysis. A third protocol uses the same triboelectric principle. However, instead of using an eraser, this microgrid protocol employs a fine polishing film to remove very small amounts of material from a sample. The last non-destructive protocol that has been published for ZooMS is the membrane box protocol. The membrane box protocol is based on contact electrification, which is the generation of electrostatic forces due to small localised differences in charge between two objects.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.